Apollomics (APLM) CFO Lin Peter Kuan-How Sells 10,000 Shares
The Chief Financial Officer of Apollomics, Inc. sold significant shares on June 15, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Lin Peter Kuan-How, Chief Financial Officer at Apollomics, Inc. ($APLM), sold 10,000 shares on June 15, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $APLM is up 64.8% after 1 week, up 38.6% after 1 month and up 52.4% to date (from the $13.85 close on Jun 15, 2026).
APLM
Apollomics, Inc.
Key Points
- Lin Peter Kuan-How, CFO of Apollomics, Inc., sold 10,000 shares on June 15, 2026.
- Apollomics, Inc. trades on NasdaqCM under APLM with a market cap of about $31.8 million.
- Recent analyst ratings include a reiterated 'buy' from H.C. Wainwright with a $17 target.
Get $APLM trade alerts by text
We text you when insiders, Congress or big funds trade $APLM. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Apollomics, Inc. alert may contain errors. Disclosures
On June 15, 2026, Lin Peter Kuan-How, the Chief Financial Officer of Apollomics, Inc. (NasdaqCM: APLM), sold 10,000 shares of the company. This insider transaction did not involve any planned sale program and occurred at a time when the stock was trading near $14.49.
Insider Buying and Selling at Apollomics, Inc.
Lin Peter Kuan-How was active on June 15, selling 10,000 shares without a planned sale program. Additionally, he sold 3,588 shares at an average price of $13.85. On the same day, he also bought 10,000 shares. Other notable insider transactions include Chen Hung-Wen, the CEO, purchasing 5,000 shares, and Chen Hong-Jung buying 500 shares.
Apollomics, Inc. Stock Down 40.4%
Shares of Apollomics, Inc. (NasdaqCM: APLM) traded near $14.49 recently. The company has a market cap of approximately $31.8 million and a forward P/E ratio of -22.29, indicating it isn't profitable. The stock has a 52-week low of $3.66 and a high of $42.12, with a 50-day moving average of $14.25 and a 200-day moving average of $16.91. The company shows a current ratio of 0.96 and a quick ratio of 0.91, reflecting its liquidity position.
Analysts Set New Price Targets
Analysts at H.C. Wainwright reiterated their 'buy' rating for Apollomics, Inc. with a price target of $17 on November 20, 2023. EF Hutton maintained a 'buy' rating with a target of $25 on May 25, 2023. These ratings suggest confidence in the company's future performance despite its current financial challenges.
About Apollomics, Inc.
Apollomics, Inc. is a clinical-stage biopharmaceutical company based in Foster City, California. Founded in 2015, it focuses on developing cancer therapies that harness the immune system and target molecular pathways. The company is working on several products, including Vebreltinib for non-small cell lung cancer and APL-102 for cancer treatment. Apollomics employs 14 people and is led by CEO Mr. Hung-Wen Chen.
Bottom Line
The insider selling by Apollomics' CFO comes as the company continues to develop its oncology therapies. Investors often watch insider transactions for potential signals about the company's prospects. However, it's important to remember that Form 13F filings and insider transactions reflect past actions and may not indicate current positions or intentions.
Related Filing Alerts
Source: Lin Peter Kuan-How's Form 4 filing on $APLM (Jun 15, 2026). Find the original filing: APLM Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts